Markets:

Overview

News

Currencies

International

Treasuries

Xilio Therapeutics, Inc. - Common Stock (NQ:XLO)

8.570 +0.220 (+2.63%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xilio Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

The trading volume of these stocks is deviating from the norm in today's session. ↗

February 13, 2025

The trading volume of these stocks is deviating from the norm in today's session.

Via Chartmill

Keep an eye on the top gainers and losers in Wednesday's session. ↗

February 12, 2025

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.

Via Chartmill

These stocks are the most active in today's session ↗

February 12, 2025

Discover the most active stocks in Wednesday's session. Stay informed about the stocks that are generating the most trading volume!

Via Chartmill

Nasdaq Edges Higher; CVS Health Shares Jump Following Upbeat Earnings ↗

February 12, 2025

Via Benzinga

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

February 12, 2025

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.

Via Chartmill

Crude Oil Down Over 2%; Upstart Shares Jump Following Earnings ↗

February 12, 2025

Via Benzinga

Traders are paying attention to the gapping stocks in Wednesday's session. ↗

February 12, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? ↗

February 12, 2025

AbbVie and Xilio partner to develop tumor-activated immunotherapies. Xilio's pipeline includes masked T cell engagers for prostate, gastric, and lung cancers.

Via Benzinga

Dow Dips Over 300 Points; US Inflation Increases More Than Expected ↗

February 12, 2025

Via Benzinga

Topics Economy Stocks

Wednesday's pre-market session: top gainers and losers ↗

February 12, 2025

As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

February 12, 2025

From Xilio Therapeutics, Inc.

Via GlobeNewswire

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

February 12, 2025

From Xilio Therapeutics, Inc.; AbbVie Inc.

Via GlobeNewswire

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 03, 2025

From Xilio Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 22, 2025

Via Benzinga

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

January 21, 2025

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 17, 2025

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 10, 2025

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗

December 20, 2024

Via Benzinga

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

December 19, 2024

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

December 16, 2024

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 03, 2024

From Xilio Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 08, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 07, 2024

Via Benzinga

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

November 07, 2024

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

November 07, 2024

From Xilio Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 30, 2024

Via Benzinga

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

October 30, 2024

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

October 04, 2024

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 02, 2024

From Xilio Therapeutics, Inc.

Via GlobeNewswire

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

August 28, 2024

From Xilio Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.